Scientific Publications Search Search Author Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Kammertöns, Thomas Dr. (4) Kopp, Joachim Dr. (2) Leisegang, Matthias Prof. Dr. rer. nat. (3) Pezzutto, Antonio Prof. Dr. (2) Siffrin, Volker (1) Uckert, Wolfgang Prof. Dr. (4) (-) Blankenstein, Thomas Prof. Dr. (13) (-) Daniel, Peter Prof. Dr. (2) (-) Willimsky, Gerald Dr. (1) 1992 (4) 1993 (7) 1994 (5) 1995 (8) 1996 (6) 1997 (9) 1998 (9) 1999 (2) 2000 (8) (-) 2001 (5) 2002 (5) 2003 (9) 2004 (8) 2005 (10) 2006 (1) 2007 (5) 2008 (5) 2009 (2) 2010 (7) (-) 2011 (5) 2012 (7) 2013 (12) 2014 (3) (-) 2015 (4) 2016 (4) 2017 (6) 2018 (5) 2019 (6) 2021 (4) 2022 (6) 2023 (4) 2024 (2) Biology of Malignant Lymphomas (10) (-) Molecular Immunology and Gene Therapy (14) Systems Biology of Gene Regulatory Elements (1) 14 Results: Active Filter: Blankenstein, Thomas Prof. Dr.Daniel, Peter Prof. Dr.Willimsky, Gerald Dr.Molecular Immunology and Gene Therapy200120112015 Sort: Result score Newest to oldest Oldest to newest January 01, 2001 / Eur J Immunol Decreased generation of anti-tumor immunity after intrasplenic immunization S. Cayeux Z.H. Qin B. Doerken T. Blankenstein January 01, 2001 / Nat Med Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay C. Becker H. Pohla B. Frankenberger T. Schueler M. Assenmacher D.J. Schendel T. Blankenstein December 03, 2001 / J Exp Med Tumor rejection by disturbing tumor stroma cell interactions S. Ibe Z.H. Qin T. Schueler S. Preiss T. Blankenstein December 17, 2001 / J Exp Med Generation of tumor-associated cytotoxic T lymphocytes requires interleukin 4 from CD8+ T cells T. Schueler T. Kammertoens S. Preiss P. Debs N. Noben-Trauth T. Blankenstein January 01, 2001 / Canc Res Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells B. Seliger U. Wollscheid F. Momburg T. Blankenstein C. Huber January 15, 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens April 01, 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto November 01, 2011 / Eur J Immunol Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors J. Charo C. Perez C. Buschow A. Jukica M. Czeh T. Blankenstein December 13, 2011 / Canc Cell Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer K. Anders C. Buschow A. Herrmann A. Milojkovic C. Loddenkemper T. Kammertoens P. Daniel H. Yu J. Charo T. Blankenstein July 28, 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein Pagination Current page 1 Page 2 Next page Next › Last page Last »
January 01, 2001 / Eur J Immunol Decreased generation of anti-tumor immunity after intrasplenic immunization S. Cayeux Z.H. Qin B. Doerken T. Blankenstein
January 01, 2001 / Nat Med Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay C. Becker H. Pohla B. Frankenberger T. Schueler M. Assenmacher D.J. Schendel T. Blankenstein
December 03, 2001 / J Exp Med Tumor rejection by disturbing tumor stroma cell interactions S. Ibe Z.H. Qin T. Schueler S. Preiss T. Blankenstein
December 17, 2001 / J Exp Med Generation of tumor-associated cytotoxic T lymphocytes requires interleukin 4 from CD8+ T cells T. Schueler T. Kammertoens S. Preiss P. Debs N. Noben-Trauth T. Blankenstein
January 01, 2001 / Canc Res Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells B. Seliger U. Wollscheid F. Momburg T. Blankenstein C. Huber
January 15, 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
April 01, 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto
November 01, 2011 / Eur J Immunol Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors J. Charo C. Perez C. Buschow A. Jukica M. Czeh T. Blankenstein
December 13, 2011 / Canc Cell Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer K. Anders C. Buschow A. Herrmann A. Milojkovic C. Loddenkemper T. Kammertoens P. Daniel H. Yu J. Charo T. Blankenstein
July 28, 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein